Formulatrix Announces Licensing Agreement
News Nov 02, 2005
Formulatrix has announced that it has entered into a global licensing agreement with the research division of Novartis for Formulatrix' Rock Maker software.
Rock Maker will integrate Novartis' entire crystallization process including experimental design, liquid handling, imaging, and data management.
Jeremy Stevenson, President of Formulatrix stated, "This deal reinforces our belief that Rock Maker is the premier software solution for automating protein crystallization. This sale also provides us with additional resources to invest into the continued development of Rock Maker."
Formulatrix specializes in providing technology that automates the protein crystallization process, a key part of structure based drug discovery. visit
Lab Innovations 2018 – Registration Opens and Keynotes AnnouncedNews
Learn and earn CPD points at the UK’s only lab-dedicated showcase and scientific seminar series.READ MORE
BioAscent Secures Investment to Expand its Integrated Drug Discovery ServicesNews
£1.6m investment recognises BioAscent’s unique capabilities.READ MORE
Research Team Discovers Compound that Stops Cancer From SpreadingNews
Using a mouse model, OHSU physician-scientists lead effort to hone a drug that inhibits cancer cells from spreading to other areas in the body.READ MORE